Prime Medicine (PRME) Interest Expenses (2021 - 2026)
Prime Medicine's (PRME) quarterly Interest Expenses came in at $179.1 million in Q1 2026, down 10.59% YoY from $200.3 million in Q1 2025, and up 5969233.33% on a QoQ basis from $3000.0 in Q4 2025.
Prime Medicine (PRME) Interest Expenses (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Interest Expenses data on file, last reported at $179.1 million in Q1 2026.
- Quarterly Interest Expenses fell 10.59% year-over-year to $179.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.1 million (down 10.59% YoY) and the FY2025 annual result came in at $3000.0, down 100.0% from the prior year.
- Interest Expenses improved to $179.1 million in Q1 2026, from $3000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $208.0 million in Q3 2024 to a low of $3000.0 in Q4 2025.
- A 5-year average of $111.4 million and a median of $119.2 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses jumped 18124.0% — and 2025, when it slumped 100.0%.
- Tracing PRME's Interest Expenses over 5 years: stood at $62.1 million in 2022, then surged by 91.93% to $119.2 million in 2023, then jumped by 50.76% to $179.8 million in 2024, then tumbled by 100.0% to $3000.0 in 2025, then surged by 5969233.33% to $179.1 million in 2026.
- The last three Interest Expenses figures came in at $179.1 million (Q1 2026), $3000.0 (Q4 2025), and $71.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 173.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 173.63 Mn |
| Jun 30, 2026 | 173.63 Mn |
| Mar 31, 2026 | 179.08 Mn |
| Mar 31, 2026 | 179.08 Mn |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 71.57 Mn |
| Sep 30, 2025 | 71.57 Mn |
| Jun 30, 2025 | 194.93 Mn |
| Jun 30, 2025 | 194.93 Mn |
| Mar 31, 2025 | 200.29 Mn |
| Mar 31, 2025 | 200.29 Mn |
| Dec 31, 2024 | 179.78 Mn |
| Dec 31, 2024 | 179.78 Mn |
| Sep 30, 2024 | 208.05 Mn |
| Sep 30, 2024 | 208.05 Mn |
| Jun 30, 2024 | 202.84 Mn |
| Jun 30, 2024 | 202.84 Mn |
| Mar 31, 2024 | 205.54 Mn |
| Mar 31, 2024 | 205.54 Mn |